1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,864 | 0,906 | 21.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 181 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 576 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 428 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 760 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 2.267 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 995 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.444 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.767 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 739 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 893 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 933 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 927 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08.25 | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.776 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen | |
| 12.06.25 | Nanoform Finland Oyj: Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide | 1.276 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | June 12, 2025 at 08:10:00 EEST
HELSINKI, FINLAND, June 12, 2025 - Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,660 | -5,48 % | Formycon startet Aflibercept-Offensive in Europa | Formycon bringt mit Ahzantive und Baiama das dritte eigenentwickelte Biosimilar auf den europäischen Markt. Die Formycon AG treibt die Kommerzialisierung ihres Biosimilar-Portfolios weiter voran. Mit... ► Artikel lesen | |
| RIBER | 13,100 | +0,15 % | Riber: Margen steigen, KI-Boom treibt - Hidden Champion vor nächsten Kursschub? | Hightech "Made in France" mit Rückenwind durch KI und Photoniks: Riber verbessert trotz leicht rückläufigem Umsatz deutlich seine Profitabilität und könnte vor einem neuen Wachstumszyklus stehen. Riber... ► Artikel lesen | |
| ONTO INNOVATION | 225,40 | +0,18 % | Onto Innovation prices $1.3B convertible senior notes offering due 2031 | ||
| KOPIN | 4,088 | -2,15 % | Fabric.AI (Nasdaq: FABC) and Kopin Corporation (Nasdaq: KOPN) Appoint Bill Maffucci to Lead Development of Neural I/o MicroLED Optical Interconnect Chip Program | NEW YORK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- Fabric.AI (Nasdaq: FABC) ("Fabric.AI" or "the Company"), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,224 | -2,61 % | Communiqué from the 2026 Annual General Meeting of Smoltek Nanotech Holding AB (publ) | ||
| GOMSPACE | 2,048 | +1,79 % | GomSpace A/S: GomSpace reports a solid Q1 with 43% revenue growth and positive EBITDA | GomSpace continues to demonstrate strong revenue growth, delivers positive EBITDA, and takes first step toward delivering sovereign satellite communication solutions in Ukraine.STOCKHOLM... ► Artikel lesen | |
| SOLESENCE | 1,255 | -0,40 % | Solésence, Inc.: Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Alle Awards, Marking Fourth Year of Recognition | ||
| XTPL | 13,200 | 0,00 % | EQS-News: XTPL S.A.: XTPL reports record-high revenues, secures further funding and focuses on sales scaling | Issuer: XTPL S.A.
/ Key word(s): Annual Results/Sales Result
XTPL reports record-high revenues, secures further funding and focuses on sales scaling
30.04.2026 / 08:26... ► Artikel lesen | |
| GAUZY | 0,680 | +1,54 % | GAUZY LTD: Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | TEL AVIV, Israel, March 20, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on March 17... ► Artikel lesen | |
| NANOVIRICIDES | 1,310 | 0,00 % | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| OBDUCAT | 0,035 | +12,90 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| VEECO INSTRUMENTS | 49,140 | -1,11 % | Veeco Instruments Inc.: Veeco Announces Upcoming Investor Events | ||
| CANATU | 7,910 | +4,63 % | Canatu Oyj: Inside information: Canatu announces a leadership transition - Dr. Maximilian Slawinski appointed as CEO and successor to Juha Kokkonen | Canatu Plc Inside information 11 May 2026 at 09:00 a.m. EEST
Inside information: Canatu announces a leadership transition - Dr. Maximilian Slawinski appointed as CEO and successor to Juha Kokkonen
Canatu's... ► Artikel lesen | |
| ACACIA RESEARCH | 3,900 | 0,00 % | Acacia Research Q1 2026 slides show mixed results, strong liquidity | ||
| NVE | 74,50 | 0,00 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen |
NANOFORM FINLAND OYJ gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 0,801 Euro und damit -1,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.